 |
110 Diseases |  |
159 Trials |
|
159 Trials |  |
1681 News |  |
| 12345678910111213...2728» |
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients with Metastatic Prostate Cancer: A Societal Perspective. (Pubmed Central) - Jun 29, 2024
According to the results of the present study, goserelin was the most effective and cost-effective strategy versus 2 other options. It could be recommended to policy makers of the Iran healthcare system to prioritize it in clinical guidelines and reimbursement policies.
- || Erleada (apalutamide) / J&J
Clinical, P2 data, Journal: Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase 2 Nonrandomized Clinical Trial, YATAGARASU. (Pubmed Central) - Jun 28, 2024
It could be recommended to policy makers of the Iran healthcare system to prioritize it in clinical guidelines and reimbursement policies. Although this study did not meet the predefined efficacy criteria, apalutamide plus goserelin showed clinically meaningful efficacy in a subset of patients with AR-positive SGC and safety consistent with prior experience in prostate cancer.
- | goserelin acetate / Generic mfg.
Journal: GOSERELIN INHIBITING UPTAKE ON SODIUM PERTECHNETATE Tc-99M THYROID SCAN: A CASE REPORT. (Pubmed Central) - Jun 28, 2024
This case report highlights a rare instance of a middle-aged woman with symptomatic toxic goitre whose sodium pertechnetate Tc-99m thyroid scan uptake was inhibited by goserelin therapy. Medical personnel caring for patients on goserelin need to be aware of the possibility of it affecting thyroid function.
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Journal: Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study. (Pubmed Central) - Jun 25, 2024
Patients maintained a good health status, with a high rate of retention of LHRHa treatment. Study number: A-ES-52014-224.A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf).
- |||| Nubeqa (darolutamide) / Bayer, Orion Corp
New P2 trial: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER DAROLUTAMIDE (ODM-201) CONCOMITANT A LA RADIOTHERAPIE CHEZ LES PATIENTS PRESENTANT UN CANCER DE LA PROSTATE A RISQUE INTERMEDIAIRE DEFAVORABLE : UNE ETUDE MULTICENTRIQUE RANDOMISEE NON-COMPARATIVE DE PHASE II (EUDRACT) - Jun 6, 2024
P2, N=62, Ongoing, Sponsor: Institut Bergoni
- ||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jun 3, 2024
P3, N=271, Active, not recruiting, Sponsor: Prof. Wolfgang Janni
Study number: A-ES-52014-224.A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf). Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
- | Kisqali (ribociclib) / Novartis
Journal, Metastases: Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer. (Pubmed Central) - May 21, 2024
Lower rates of symptomatic adverse events were observed in the ribociclib versus CT arm. First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2- ABC.
- | goserelin acetate / Generic mfg.
Journal: Electrochemical DNA-nano biosensor for the detection of Goserelin as anticancer drug using modified pencil graphite electrode. (Pubmed Central) - May 16, 2024
Furthermore, the molecular docking investigation highlighted that Goserelin is able to bind ds-DNA preferentially and supported the findings of the experiments. The determining of Goserelin in real samples has been effectively accomplished in the last phase using ds-DNA/PA/CuO/MWCNTs/PGE.
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Ibrance (palbociclib) / Pfizer
ARREST (Lomond Auditorium) - May 8, 2024 - Abstract #ESTRO2024ESRTO_44;
P1
The ARREST study demonstrated that SABR treatment to all sites of polymetastatic disease is feasible in selected patients. Doses up to 30 Gy in 5 fractions were delivered with minimal acute toxicity noted.
- | Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati, Rubraca (rucaparib) / Pharma& Schweiz
Journal: Multicriteria decision making attributes and estimation of physicochemical properties of kidney cancer drugs via topological descriptors. (Pubmed Central) - May 7, 2024
This leads towards new opportunities to paved the way for drug discovery and the formation of efficient and suitable treatment options in therapeutic targeting. We also employed multicriteria decision making techniques like COPRAS and PROMETHEE-II for ranking of said disease treatment drugs and physicochemical characteristics.
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Retrospective data, Journal, Real-world evidence, Real-world: Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study. (Pubmed Central) - May 6, 2024
The effectiveness of the three GnRHa depots commonly used in China seems comparable. Younger patients face a heightened risk of insufficient OFS.
- Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6812;
Despite differences in mode of administration, findings indicate that persistence and adherence are similar in pts with PC treated with REL and GnRH agonists while higher than those treated with DEG. Future research is needed to understand the factors associated with persistence and adherence.
- goserelin acetate / Generic mfg., triptorelin / Generic mfg.
Adherence to fertility preservation guidelines in young patients with breast cancer: A retrospective analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4641;
While estrogen receptor status is crucial for determining treatment suitability, GnRH analog utilization was notably low among triple-negative breast cancer patients. This suggests that triple-negative status alone should not preclude GnRH analog use.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial. (Hall A; Poster Bd #: 210a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1353;
P2/3
Considering an 80% SD rate post two neoadjuvant TAC cycles and a 10% attrition, the sample size was ultimately set at 119. The trial is actively recruiting.
- Kisqali (ribociclib) / Novartis
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2? early breast cancer (EBC): NATALEE trial. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1240;
P3
These findings support the use of RIB in pts with HR+/HER2? EBC at increased risk of recurrence, including pts with N0 disease.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed, Combination therapy, Metastases: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) - Apr 24, 2024
P2, N=60, Active, not recruiting, Sponsor: Xiao X. Wei, MD
EBC at increased risk of recurrence, including pts with N0 disease. Recruiting --> Active, not recruiting
- ||||||||| Kisqali (ribociclib) / Novartis
Trial suspension: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Apr 23, 2024
P3, N=3100, Suspended, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Suspended
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, HEOR, Combination therapy: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Apr 17, 2024
P2, N=257, Completed, Sponsor: Palleos Healthcare GmbH
Recruiting --> Suspended Active, not recruiting --> Completed
- ||| Biomarker, Enrollment closed: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Apr 16, 2024
P2, N=550, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Metastases: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (clinicaltrials.gov) - Apr 8, 2024
P2, N=79, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Soltamox (tamoxifen citrate) / Jazz, Perjeta (pertuzumab) / Roche
New P2 trial, Surgery: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov) - Apr 4, 2024
P2, N=74, Not yet recruiting, Sponsor: University of Chicago
- |||| Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Mar 27, 2024
P3, N=412, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Recruiting --> Active, not recruiting Trial completion date: Jan 2030 --> Aug 2029 | Trial primary completion date: Jan 2030 --> Aug 2029
- | Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date: ImmunoADAPT: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Mar 27, 2024
P2, N=33, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jan 2030 --> Aug 2029 | Trial primary completion date: Jan 2030 --> Aug 2029 Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
- |||| Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Metastases: A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-na (clinicaltrials.gov) - Mar 26, 2024
P=N/A, N=979, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2024 Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 26, 2024
P3, N=315, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025 Trial completion date: Dec 2023 --> Dec 2024
- | goserelin acetate / Generic mfg.
Observational data, Journal: Premature luteinization and pregnancy outcomes in depot goserelin-downregulated assisted reproductive technology cycles: A cross-sectional study from Ethiopia. (Pubmed Central) - Mar 25, 2024
Trial completion date: Dec 2023 --> Dec 2024 A depot goserelin-downregulated long protocol for IVF is a cost-effective and convenient option for controlled ovarian hyperstimulation without increased risk of having premature luteinization compared to antagonist and minimal stimulation protocols.
- | Kisqali (ribociclib) / Novartis
Journal: Ribociclib plus Endocrine Therapy in Early Breast Cancer. (Pubmed Central) - Mar 24, 2024
P3
Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: PATHWAY: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (clinicaltrials.gov) - Mar 22, 2024
P3, N=180, Active, not recruiting, Sponsor: National Cancer Center, Japan
(Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.). Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
- || goserelin acetate / Generic mfg.
Trial completion date, Trial primary completion date: Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer (clinicaltrials.gov) - Mar 21, 2024
P=N/A, N=25, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Apr 2025 --> Sep 2025 Trial completion date: Jan 2030 --> Jan 2031 | Trial primary completion date: Apr 2025 --> Apr 2026
- | Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: FINEST: A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC (clinicaltrials.gov) - Mar 21, 2024
P1/2, N=20, Recruiting, Sponsor: Fudan University
Trial completion date: Jan 2030 --> Jan 2031 | Trial primary completion date: Apr 2025 --> Apr 2026 Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
- goserelin acetate / Generic mfg.
Goserelin 10.8 mg and 3.6 mg Depots in Breast Cancer (BC): A Large Real-World Noninferiority Study (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_378;
Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024 This large RWS with rigorous design validated the noninferiority of goserelin 10.8 mg 3-monthly to 3.6 mg monthly in Chinese pts with HR+ BC.
- Kisqali (ribociclib) / Novartis
NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2_ early breast cancer (EBC) (Hamburg Hall) - Mar 14, 2024 - Abstract #ESMOBC2024ESMO_BC_247;
With the majority of pts completing RIB tx, these data confirm that RIB-related AEs and dose-related adjustments occurred early, highlighting the importance of timely management of AEs. RIB was well-tolerated in NATALEE with current dose adjustment guidelines.
- goserelin acetate / Generic mfg.
Management of prostate cancer is associated with significant healthcare costs (302A) - Mar 12, 2024 - Abstract #AUA2024AUA_1672;
Efforts must be dedicated to screening and prevention and policymakers should be aware of the economic impact of the disease when budgetary allocations are made. It is also important to note that Black men presented with prostate cancer at higher rates in both the acute and outpatient settings, highlighting the disproportionate nature of the disease and progression.
- Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6650;
It is also important to note that Black men presented with prostate cancer at higher rates in both the acute and outpatient settings, highlighting the disproportionate nature of the disease and progression. Abstract is embargoed at this time.
- || Nubeqa (darolutamide) / Bayer, Orion Corp, Verzenio (abemaciclib) / Eli Lilly
Enrollment closed: Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer (clinicaltrials.gov) - Feb 28, 2024
P1/2, N=93, Active, not recruiting, Sponsor: Praful Ravi, MB BCHir, MRCP
Abstract is embargoed at this time. Recruiting --> Active, not recruiting
- |||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati, Firmagon (degarelix) / Astellas, Ferring
New P2/3 trial: THUNDER: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (clinicaltrials.gov) - Feb 28, 2024
P2/3, N=493, Recruiting, Sponsor: Cancer Research Antwerp
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 22, 2024
P3, N=3100, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, donanemab (LY3002813) / Eli Lilly
Journal: In Silico Investigation of Novel Compounds as Inhibitors of Acetylcholinesterase Enzyme for the Treatment of Alzheimer's Diseases. (Pubmed Central) - Feb 19, 2024
Currently, two immunotherapy drugs that target amyloid protein (donanemab and lecanemab) are being considered for the treatment of Alzheimer's disease at an early stage...Finally, further literature studies revealed that Zoladex affects memory reduction; therefore, it was dropped as a possible repurposed drug. Our research showed that CHEMBL-1240685 is a potential compound that could be investigated for the inhibition of anticholinesterase enzyme and might be another drug molecule that could be used to treat Alzheimer's disease.
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 19, 2024
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Our research showed that CHEMBL-1240685 is a potential compound that could be investigated for the inhibition of anticholinesterase enzyme and might be another drug molecule that could be used to treat Alzheimer's disease. Trial completion date: Dec 2023 --> Dec 2024
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=3100, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Jul 2028 --> Sep 2029
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: BTCRC-HN17-111: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=20, Recruiting, Sponsor: Manish Patel
Trial primary completion date: Jul 2028 --> Sep 2029 Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Combination therapy: SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov) - Feb 15, 2024
P2, N=202, Recruiting, Sponsor: Cancer Research Antwerp
Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025
- ||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion, Enrollment change, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Feb 9, 2024
P=N/A, N=960, Completed, Sponsor: Bayer
Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025 Active, not recruiting --> Completed | N=400 --> 960
- | everolimus / Generic mfg.
Enrollment open, Metastases: BCTOP-L-M01: Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (clinicaltrials.gov) - Feb 8, 2024
P2, N=265, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed | N=400 --> 960 Not yet recruiting --> Recruiting
- | goserelin acetate / Generic mfg.
Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer. (Pubmed Central) - Feb 6, 2024
Not yet recruiting --> Recruiting Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.
- | docetaxel / Generic mfg.
Trial completion, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jan 31, 2024
P1, N=20, Completed, Sponsor: Medical University of South Carolina
Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer. Active, not recruiting --> Completed
- | Synarel (nafarelin) / Pfizer
Journal, Machine learning: Anti-Dengue: A Machine Learning-Assisted Prediction of Small Molecule Antivirals against Dengue Virus and Implications in Drug Repurposing. (Pubmed Central) - Jan 27, 2024
We identified goserelin, gonadorelin, and nafarelin as potential repurposed drugs with high pIC50 values. "Anti-Dengue" may be beneficial in accelerating antiviral drug development against the dengue virus.
- |||| New P2 trial: ESCALATE: Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients (clinicaltrials.gov) - Jan 25, 2024
P2, N=124, Not yet recruiting, Sponsor: National Taiwan University Hospital
- Kisqali (ribociclib) / Novartis
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2? early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_30;
Efficacy results confirm continued improvement in benefit across subgroups, including stage II disease. Safety findings support the manageable toxicity profile of RIB at the 400-mg starting dose in early breast cancer.
- Kisqali (ribociclib) / Novartis
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_29;
P3
The NATALEE results support ribociclib + ET as the treatment of choice in a broad population of pts with stage II or III HR+/HER2? EBC, including pts with N0 disease